We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New COVID-19 Test That Identifies T-Cell Signature Better at Detecting Past Coronavirus Infection

By LabMedica International staff writers
Posted on 12 Nov 2020
Print article
Illustration
Illustration
New research shows that the unique properties of T cells could make a test that detects virus-specific T cells in a more effective way to assess SARS-CoV-2 exposure before antibodies arise and after they wane.

Using a set of identified “shared” T-cell receptors (TCRs) that are seen across multiple individuals infected with COVID-19, Adaptive Biotechnologies (Seattle, WA, USA) has identified a T-cell signature that can be used for diagnostic purposes. The company is developing a T-cell based diagnostic test that can that detect virus-specific T cells in a more effective way to assess SARS-CoV-2 exposure before antibodies arise and after they wane.

Adaptive recently conducted a head-to-head study in a real-world setting comparing the company’s T-cell test under development with two leading serology tests in 100 patients, ranging from active infection through convalescence. The tests were set at 99.8% specificity to minimize false positives. In the study, 94% of patients were detected as positive by Adaptive’s T-cell test under development vs. 90% (IgG and IgM) and 87% (IgG only) for the serology tests, respectively.

These results, together with a growing body of evidence indicating T cells can be present in the absence of antibodies, suggest the potential utility of Adaptive’s T-cell based approach to detect immune response to SARS-CoV-2 earlier, and in less severe cases, than tests that detect antibody response. Adaptive is currently working with the FDA to generate and package the data required to submit for Emergency Use Authorization (EUA). The company anticipates that the data it continues to generate will expand the clinical applications for its T-cell based testing approach to potentially include assessing pre-existing immunity based on cross-reactive T cells, post infection immunity, and immunity from a vaccine, which may need to be monitored for possible boosters over time.

Related Links:
Adaptive Biotechnologies

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more